Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension

Chest

Volumn 141, Issue 3, 2012, Pages 651-660

  Bartelds, Beatrijs ^a   Van Loon, Rosa Laura E ^a   Mohaupt, Saffloer ^a   Wijnberg, Hans ^a   Dickinson, Michael G ^a   Boersma, Bibiche ^a   Takens, Janny ^a   Van Albada, Mirjam ^a   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; CROMOGLYCATE DISODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MAST CELL; MAST CELL DEGRANULATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR REMODELING; RAT; RESPIRATORY TRACT DISEASE;

EID: 84857976204     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0663     Document Type: Article

References (41)

1. Berger RM. Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J. 2000;21(1):17-27. (Pubitemid 30042664)
2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
3. Wagenvoort CA, Mooi WJ. In: Munro Neville A, Walker F, Gottlieb LS, eds. Biopsy Pathology of the Pulmonary Vasculature. London, England:Chapman and Hall Medical; 1989:56-113.
4. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297(6):L1013- L1032.
5. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol. 2007;2:369-399. (Pubitemid 46448070)
6. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S20-S31.
7. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation. 2008;118(14):1486-1495.
8. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
9. van Albada ME, Bartelds B, Wijnberg H, et al. Gene expression profile in flow-associated pulmonary arterial hypertension with neointimal lesions. Am J Physiol Lung Cell Mol Physiol. 2010;298(4):L483-L491.
10. Metz M, Maurer M. Mast cells-key effector cells in immune responses. Trends Immunol. 2007;28(5):234-241. (Pubitemid 46654869)
11. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(suppl 1):S10-S19.
12. Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med. 1999;160(4):1303-1308. (Pubitemid 29487474)
13. Vaszar LT, Nishimura T, Storey JD, et al. Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats. Physiol Genomics. 2004;17(2):150-156. (Pubitemid 38924161)
14. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13(11):1382-1397. (Pubitemid 29270244)
15. Kishi K, Jin D, Takai S, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res. 2006;60(1):77-82. (Pubitemid 44297617)
16. Banasová A, Maxová H, Hampl V, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration. 2008;76(1): 102-107. (Pubitemid 351914146)
17. Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol. 2004; 15(5):567-573. (Pubitemid 39336585)
18. Roofthooft MT, Bergman KA, Waterbolk TW, Ebels T, Bartelds B, Berger RM. Persistent pulmonary hypertension of the newborn with transposition of the great arteries. Ann Thorac Surg. 2007;83(4):1446-1450. (Pubitemid 46440761)
19. van Albada ME, Schoemaker RG, Kemna MS, Cromme-Dijkhuis AH, van Veghel R, Berger RM. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J. 2005;26(3):487-493. (Pubitemid 41264214)
20. van Albada ME, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG, Berger RM. Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling. J Cardiovasc Pharmacol. 2006;48(5):249-254.
21. Kanemitsu H, Takai S, Tsuneyoshi H, et al. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 2006;29(1) : 57-64.
22. Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodeling in pulmonary hypertension. Eur Respir J. 2011;37(6):1400-1410.
23. Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2010;43(6):629-634.
24. Galiè N, Beghetti M, Gatzoulis MA, et al;Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114(1):48-54.
25. Simonneau G, Barst RJ, Galie N, et al;Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6): 800-804. (Pubitemid 34229650)
26. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171-1177.
27. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182(5):652-660.
28. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124-1131.
29. Trivedi NN, Caughey GH. Mast cell peptidases: chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol. 2010;42(3):257-267.
30. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13(10):1211-1218. (Pubitemid 47530639)
31. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007;13(6):719-724. (Pubitemid 46889760)
32. Tozzi CA, Thakker-Varia S, Yu SY, et al. Mast cell collagenase correlates with regression of pulmonary vascular remodeling in the rat. Am J Respir Cell Mol Biol. 1998;18(4): 497-510. (Pubitemid 128353623)
33. Maryanoff BE, de Garavilla L, Greco MN, et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med. 2010;181(3):247-253.
34. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15(8):940-945.
35. Ramos L, Peña G, Cai B, Deitch EA, Ulloa L. Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol. 2010;185(1):709-716.
36. Humbert M, Hoeper MM. Severe pulmonary arterial hypertension: a forme fruste of cancer? Am J Respir Crit Care Med. 2008;178(6):551-552.
37. O'Callaghan DS, Savale L, Jais X, et al. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respir Med. 2010;104(suppl 1):S74-80.
38. Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD. Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med. 1998;158(3):939-950. (Pubitemid 28449464)
39. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci. 2009; 110(4):459-465.
40. Tashiro K, Takai S, Jin D, et al. Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine-and choline-deficient diet. Hepatol Res. 2010;40(5) : 514-523.
41. Palaniyandi SS, Nagai Y, Watanabe K, et al. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med (Maywood). 2007;232(9) : 1213-1221. (Pubitemid 47503062)